Even As Acting US FDA Commissioner, Woodcock Still Holds Multiple Positions
Executive Summary
To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.
You may also be interested in...
US FDA Chief Of Staff Returning To CBER For Deputy Director Role
Julie Tierney will become CBER’s deputy director for strategy, policy and legislation, a newly created position.
US FDA Leadership Team: Woodcock’s Next Chapter
The announcement of US FDA Deputy Commissioner’s new focus going forward at the agency may not mean what you think it does. The focus shouldn’t be on what Janet Woodcock is not doing – but on the fact that she is staying on at the agency at all.
US FDA Mum On Whether Woodcock Would Stick Around Long-Term For Califf
Woodcock’s willingness to stay on at US FDA for more than a transitional period after Robert Califf’s expected confirmation as commissioner may depend on exactly the type of authority and tasks he’d be willing to delegate to her. Plus, some other agency personnel updates.